Soleno Therapeutics (SLNO) Cash from Financing Activities (2014 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Cash from Financing Activities data on file, last reported at -$1.0 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 132.41% year-over-year to -$1.0 million in Q1 2026; TTM through Mar 2026 was $132.9 million, a 38.27% decrease from a year earlier, with the FY2025 full-year figure at $137.2 million, down 35.61% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.0 million, up from -$99.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for SLNO reached as high as $218.2 million in Q3 2025 and fell as low as -$99.9 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $36.2 million across 5 years, with a median of $14.0 million in 2022.
• Across the five-year window, Cash from Financing Activities plunged 14200.0% in 2022 and jumped 11420.76% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $342000.0 in 2022, then soared by 36028.07% to $123.6 million in 2023, then tumbled by 53.82% to $57.1 million in 2024, then sank by 275.07% to -$99.9 million in 2025, then jumped by 98.96% to -$1.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.0 million in Q1 2026, -$99.9 million in Q4 2025, and $218.2 million in Q3 2025.